Dr. Reddy's Laboratories has paused commercial supply of its Semaglutide API to partner OneSource due to an identified impurity. While patient safety is unaffected, this will impact near-term financial guidance. Supply is expected to resume by late 2026.
Dr. Reddy's Laboratories Halts Semaglutide API Supply Due to Impurity
Dr. Reddy's Laboratories has identified an impurity in a new scale-up batch of its Semaglutide Active Pharmaceutical Ingredient (API). This has led to a halt in commercial supply to its partner, OneSource. The company anticipates resuming commercial supply by late October or early November 2026.
Reader Takeaway: Supply halt impacts near-term earnings; patient safety remains unaffected.
What just happened
Dr. Reddy's Laboratories has stopped commercial supply of Semaglutide API to its partner OneSource. This action was taken after an impurity was detected during the testing of a new scale-up batch.
The company is currently conducting three validation batches to re-validate the manufacturing process, a process expected to continue through September 2026.
Why this matters
The temporary supply halt is expected to negatively affect Dr. Reddy's previously issued financial guidance for the current period. The company may also need to write down specific batches of inventory held at OneSource that are associated with the out-of-specification issue.
However, management has confirmed there is no impact on patient safety, as the affected batches never reached the market. No regulatory agency notification or new approvals are required for the re-validation process.
The backstory
This issue pertains to the Semaglutide API scale-up batch. Dr. Reddy's has clarified that the supply of Semaglutide oral tablets will not be affected, as these use a different API source.
The company remains committed to OneSource as a long-term partner.
What changes now
Commercial supply to OneSource is paused and is expected to resume in late 2026. The company is undertaking a thorough investigation and process improvement.
Management indicated that some commercial terms regarding down payments with OneSource may require renegotiation, though no penalties are anticipated.
Risks to watch
- Validation Risk: Any further delays in the re-validation process could push the supply resumption timeline beyond the current estimate.
- Financial Headwind: Potential inventory write-downs and lower supply volumes in the coming months will impact near-term financial results.
Peer comparison
Information regarding peer API supply issues for Semaglutide is not available in the filing. The company has highlighted that global demand for the product remains strong.
Context metrics (time-bound)
- Projected Supply (Nov 2026 to Mar 2027): 6-7 million pens.
- Re-validation process expected to continue through September 2026.
- Commercial supply resumption expected late October/early November 2026.
What to track next
Investors should monitor the timeline for the completion of the re-validation process and the actual commencement of supply to OneSource. Updates on the financial impact will be closely watched in upcoming quarterly results.